Background: Clinicians face uncertainty about the prognostic value of troponin testing in
patients with chronic kidney disease (CKD) without suspected acute coronary syndrome …

Fibroblast growth factor 23 (FGF23) is a hormone released primarily by osteocytes that
regulates phosphate and vitamin D metabolism. Recent observational studies in humans …

In recent years, numerous biomarkers have been studied in heart failure to improve
diagnostic accuracy and identify patients at higher risk. The overall outcome remains fairish …

Kidney function undergoes developmental changes, including postnatal adaptation of
nephron recruitment until approximately 18 months of age and glomerular hypertrophy …

By demonstrating direct pathological effects of FGF23 on the heart, novel findings from a
recent translational study reposition FGF23 from biomarker of risk, to mechanism of disease …

BACKGROUND: Detectable levels of cardiac troponins are common in individuals with
chronic kidney disease (CKD), even in the absence of symptomatic cardiovascular disease …

Fibroblast growth factor 23 and adverse clinical outcomes in... : Current Opinion in Nephrology
and Hypertension Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney …

Cardiovascular disease is associated with increased fracture risk in the general population.
Few data exist on the association between cardiovascular health and incident fracture risk in …

Background Fibroblast growth factor-23 (FGF-23), a novel marker of bone disease in chronic
kidney disease (CKD) has been shown to correlate with vascular calcifications. We aimed to …

Background. Patients undergoing hemodialysis and kidney graft recipients are high-risk
populations for cardiovascular and all-cause mortality. Fibroblast growth factor 23 (FGF23) …